Notice: This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends ORPN vs. KTTA, ERNA, GLMD, QNRX, ADTX, TRVN, ONCT, PBLA, SXTC, and VRPXShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Pasithea Therapeutics (KTTA), Eterna Therapeutics (ERNA), Galmed Pharmaceuticals (GLMD), Quoin Pharmaceuticals (QNRX), Aditxt (ADTX), Trevena (TRVN), Oncternal Therapeutics (ONCT), Panbela Therapeutics (PBLA), China SXT Pharmaceuticals (SXTC), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "medical" sector. Bioblast Pharma vs. Pasithea Therapeutics Eterna Therapeutics Galmed Pharmaceuticals Quoin Pharmaceuticals Aditxt Trevena Oncternal Therapeutics Panbela Therapeutics China SXT Pharmaceuticals Virpax Pharmaceuticals Bioblast Pharma (NASDAQ:ORPN) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Does the media prefer ORPN or KTTA? In the previous week, Bioblast Pharma's average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score. Company Overall Sentiment Bioblast Pharma Neutral Pasithea Therapeutics Neutral Does the MarketBeat Community prefer ORPN or KTTA? Bioblast Pharma received 210 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 78.23% of users gave Bioblast Pharma an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformBioblast PharmaOutperform Votes21278.23% Underperform Votes5921.77% Pasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Do insiders and institutionals hold more shares of ORPN or KTTA? 4.5% of Bioblast Pharma shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, ORPN or KTTA? Bioblast Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Which has better earnings and valuation, ORPN or KTTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioblast PharmaN/AN/A-$5.94MN/AN/APasithea TherapeuticsN/AN/A-$15.96MN/AN/A Is ORPN or KTTA more profitable? Bioblast Pharma's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bioblast PharmaN/A N/A N/A Pasithea Therapeutics N/A -81.57%-74.31% SummaryBioblast Pharma beats Pasithea Therapeutics on 6 of the 8 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$420,000.00$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A6.1126.7419.18Price / SalesN/A268.29435.4670.76Price / CashN/A65.6738.0134.83Price / Book0.136.707.644.62Net Income-$5.94M$138.98M$3.19B$246.06M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.00-1.8%N/A-68.9%$420,000.00N/A0.00N/AHigh Trading VolumeKTTAPasithea Therapeutics0.7679 of 5 stars$1.37-5.5%N/A-82.7%$1.74MN/A0.003ERNAEterna TherapeuticsN/A$0.30-1.4%N/A-80.4%$1.64M$598,000.00-0.0410Positive NewsGap UpGLMDGalmed Pharmaceuticals0.7033 of 5 stars$2.56-2.3%N/A-41.3%$1.64MN/A-0.1520QNRXQuoin Pharmaceuticals3.2484 of 5 stars$0.31+0.5%$4.00+1,190.3%-88.8%$1.57MN/A-0.084ADTXAditxt0.923 of 5 stars$0.11+57.1%N/A-99.9%$1.57M$640,000.000.0060News CoverageGap DownHigh Trading VolumeTRVNTrevena0.8587 of 5 stars$1.82+0.6%$5.00+174.7%-88.2%$1.57M$3.12M-0.0440Gap DownONCTOncternal Therapeutics1.5303 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530PBLAPanbela TherapeuticsN/A$0.32-6.0%N/A-63.6%$1.55MN/A0.006SXTCChina SXT Pharmaceuticals0.2015 of 5 stars$0.38-1.0%N/A-82.9%$1.54M$1.93M0.0090Stock SplitNegative NewsVRPXVirpax Pharmaceuticals1.4418 of 5 stars$0.31-5.0%$3.00+867.7%-91.2%$1.52MN/A0.007Gap Up Related Companies and Tools Related Companies Pasithea Therapeutics Competitors Eterna Therapeutics Competitors Galmed Pharmaceuticals Competitors Quoin Pharmaceuticals Competitors Aditxt Competitors Trevena Competitors Oncternal Therapeutics Competitors Panbela Therapeutics Competitors China SXT Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORPN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
